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Abstract 
The development of drugs to improve cognition in patients with schizophrenia is a major unmet clinical 
need. A number of promising compounds failed in recent clinical trials, a pattern linked to poor translation 
between preclinical and clinical stages of drug development. Seeking proof of efficacy in early Phase 1 
studies in surrogate patient populations (for example, high schizotypy individuals where subtle cognitive 
impairment is present) has been suggested as a strategy to reduce attrition in the later stages of drug 
development. However, there is little agreement regarding the pattern of distribution of schizotypal 
features in the general population, creating uncertainty regarding the optimal control group that should be 
included in prospective trials. We aimed to address this question by comparing the performance of 
groups derived from the general population with low, average and high schizotypy scores over a range of 
cognitive and oculomotor tasks. We found that tasks dependent on frontal inhibitory mechanisms (N-
Back working memory and anti-saccade oculomotor tasks), as well as a smooth-pursuit oculomotor task 
were sensitive to differences in the schizotypy phenotype. In these tasks the cognitive performance of 
'low schizotypes' was significantly different from 'high schizotypes' with 'average schizotypes' having an 
intermediate performance. These results indicate that for evaluating putative cognition enhancers for 
treating schizophrenia in early-drug development studies the maximum schizotypy effect would be 
achieved using a design that compares low and high schizotypes. 
Keywords 
implications, schizotypy, high, low, subjects, performance, oculomotor, studies, cognitive, development, 
drug, translational 
Disciplines 
Education | Social and Behavioral Sciences 
Publication Details 
Koychev, I., Joyce, D., Barkus, E., Ettinger, U., Schmechtig, A., Dourish, C. T., Dawson, G. R., Craig, K. J. & 
Deakin, J. W. (2016). Cognitive and oculomotor performance in subjects with low and high schizotypy: 
implications for translational drug development studies. Translational Psychiatry, 6 e811-1-e811-8 
Authors 
Ivan Koychev, D Joyce, Emma Barkus, Ulrich Ettinger, Anne Schmechtig, Colin Dourish, Gerard Dawson, 
Kevin Craig, and John Francis Deakin 
This journal article is available at Research Online: https://ro.uow.edu.au/sspapers/2197 
OPEN
ORIGINAL ARTICLE
Cognitive and oculomotor performance in subjects
with low and high schizotypy: implications for
translational drug development studies
I Koychev1,2, D Joyce3, E Barkus4,5, U Ettinger6, A Schmechtig7, CT Dourish8, GR Dawson8, KJ Craig8 and JFW Deakin1
The development of drugs to improve cognition in patients with schizophrenia is a major unmet clinical need. A number of
promising compounds failed in recent clinical trials, a pattern linked to poor translation between preclinical and clinical stages of
drug development. Seeking proof of efficacy in early Phase 1 studies in surrogate patient populations (for example, high schizotypy
individuals where subtle cognitive impairment is present) has been suggested as a strategy to reduce attrition in the later stages of
drug development. However, there is little agreement regarding the pattern of distribution of schizotypal features in the general
population, creating uncertainty regarding the optimal control group that should be included in prospective trials. We aimed to
address this question by comparing the performance of groups derived from the general population with low, average and high
schizotypy scores over a range of cognitive and oculomotor tasks. We found that tasks dependent on frontal inhibitory mechanisms
(N-Back working memory and anti-saccade oculomotor tasks), as well as a smooth-pursuit oculomotor task were sensitive to
differences in the schizotypy phenotype. In these tasks the cognitive performance of ‘low schizotypes’ was significantly different
from ‘high schizotypes’ with ‘average schizotypes’ having an intermediate performance. These results indicate that for evaluating
putative cognition enhancers for treating schizophrenia in early-drug development studies the maximum schizotypy effect would
be achieved using a design that compares low and high schizotypes.
Translational Psychiatry (2016) 6, e811; doi:10.1038/tp.2016.64; published online 17 May 2016
INTRODUCTION
Cognitive impairment is a core symptom of schizophrenia that
predicts functional outcome1–3 and treatment adherence.4
However, it is largely unaffected by currently available medica-
tion5 and the development of drugs to treat cognitive deficits in
schizophrenia is a recognised unmet need.6
Although a number of putative cognitive enhancers have been
examined in trials none have been approved for treatment.7 Lack
of clinical efficacy was the main reason for attrition revealing a
critical gap in translating efficacy evidence from animal models to
patients. One strategy to address this is to assess efficacy at Phase
1 of drug development and discontinue development if no
efficacy is demonstrated thus saving time and resources from
Phase 2 and 3 trials.8 Such experimental or translational medicine
studies use biomarkers of the proposed core pathophysiology as
proxies of efficacy rather than traditional clinical end-points to
shorten the time needed to reach ‘Go/No-Go’ decisions.9 This
approach can be complemented by selecting either patients
who are more likely to respond (mild symptomatology or
medication-free) or subclinical healthy volunteers that lack the
confounds of patient groups (for example, heterogeneous
symptom and medication profiles).
In the case of schizophrenia, early assessment of cognitive
enhancers efficacy can be sought in surrogate patient populations
such as individuals with high levels of schizotypy.10–12 Schizotypy
is a term coined by Meehl13 under the influence of Rado14 and is
used to describe a latent personality structure associated with
schizophrenia risk with the affected individuals referred to as
‘schizotypes’.13 The severity of these features range along a
continuum that funnels into overt psychosis at its extreme.15–17
Schizophrenia and schizotypy share a common genetic basis18–20
and have a number of neurobiological similarities.21,22 These
encompass changes in grey23,24 and white25,26 matter morphology
but also neurobiological function,27–30 including cognition.24,31–34
Various lines of evidence point to a relative weakness of frontal
inhibitory mechanisms being a key unifying feature of the
schizophrenia spectrum nervous system, a phenomenon
described in patients as far back as Bleuler.35 In schizotypy this
manifests itself in impaired performance on inhibitory tasks (for
example, negative priming (NP),36,37 lateral inhibition38 and the
anti-saccade eye-movement task39,40) as well as working memory
(WM) tests33,41–44 where inhibition of competing stimuli is crucial
for successfully maintaining and manipulating information
‘online’. Fine motor control is another neurocognitive function
dependent on frontal input that defines schizophrenia spectrum:
schizotypal individuals,45,46 as well as patients47 have difficulties
performing tasks such as smooth eye pursuit where the eyes are
guided to follow a moving target. Despite these similarities high
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schizotypes (HS) are generally spared psychotic episodes,
repeated hospitalisations and chronic antipsychotic treatment.48
Importantly, for cognitive experiments intelligence quotient (IQ)
and educational levels are within the normal population range.49
The combination of schizophrenia spectrum neurobiology and
lack of confounds makes HS important surrogates for establishing
early evidence of cognitive enhancer efficacy.10,11
Standardised questionnaires such as the Schizotypal Personality
Questionnaire (SPQ),50 can be used to identify schizotypy
psychometrically in the general population.51,52 While the SPQ
was designed to identify Schizotypal Personality Disorder (SPD)
according to DSM-III-R, in practice high SPQ scorers tend to
represent a broader schizotypy group with only ~ 55% of them
attracting a diagnosis of SPD.50 A number of other scales are
available53–58 but the SPQ is preferred due to the well-established
normative data.59,60 A methodological issue with psychometrically
identified schizotypy, however, is that cognitive dysfunction may
not be readily demonstrable as a meta-analysis in college students
reported.61 This is an important pragmatic consideration as
experimental medicine studies depend on reliable, well defined
group differences in performance to merit inclusion in the drug
development process.62,63 A potential route towards maximising
the potential return on investment in an experimental medicine
approach is to investigate whether a particular comparator group
yields stronger effects in comparisons with schizotypes. To date
large schizotypy studies have focussed on recruiting subjects with
average schizotypy scores as comparators reasoning that indivi-
duals with low scores may exhibit atypical performance on
cognitive tasks.61,62 This reflects the existence of two alternative
theories describing the relationship between schizotypy and
schizophrenia. A ‘quasi-dimensional’ framework proposes that
~ 10% of the general population have key neural changes
(‘schizotaxia’) that manifest in the development of schizophrenia
or extreme schizotypal symptoms.17,64 According to this model,
there is no difference in the neurocognitive performance of
healthy volunteers with the exception of individuals with extreme
schizotypal symptoms. In contrast a ‘fully dimensional’ framework
proposes that schizotypal personality traits and its associated
neurocognitive changes exist on a continuum from healthy
individuals to patients with schizophrenia.65,66 According to this
model, average schizotypes (AS) have an intermediate cognitive
performance relative to HS and low schizotypes (LS).
In the present study, we aimed to establish whether individuals
with low or average schizotypy should be used as comparators in
studies evaluating putative cognitive enhancers in HS. Thus, we
compared the cognitive performance of low, average and HS on a
range of cognitive measures (testing inhibitory function and
motor control). Based on recent evidence supporting the fully
dimensional framework of schizotypy,67–69 we hypothesised that
LS would be the comparator group that would yield the more
robust statistical difference in comparison with HS.
MATERIALS AND METHODS
Subjects, study criteria and design
The study included three groups of participants based on their schizotypy
scores as measured by the SPQ (HS, AS and LS defined as scores of 441,
21–36 and ⩽ 9, respectively). SPQ was chosen as pilot studies had
confirmed the sensitivity of SPQ to the factors of interest and enabled us to
power the present study to detect significant results.59 The HS and AS were
recruited within a larger, multi-center study investigating the effects of
risperidone, amisulpride and nicotine on cognition in schizotypy. LS were
recruited specifically for the purposes of the current analysis.
As part of the procedures of the larger study, AS and HS were recruited
from three sites in the United Kingdom (Manchester, London and Cardiff)
via an online version of the SPQ in its short70 and full version.50 The online
questionnaire was advertised via university research volunteering e-mails,
social networking sites and advertisements in local media. Participants
were screened by telephone for significant mental health and medical
history. Included participants were invited to a screening appointment at
which consent was obtained and the full SPQ was completed again
(regardless of whether they had completed the short or full SPQ online).
Participants were assigned to the AS or HS groups on the basis of the
screening visit full SPQ score only. Other inclusion criteria at the screening
visit were age between 18 and 45 years, fluency in the English language,
no relevant medical history and body mass index in the range of 18–30.
Exclusion criteria were history or presence of mental health disorders
(screened for using the Mini-International Neuropsychiatric Interview71),
daily consumption of more than five cigarettes or eight standard
caffeinated drinks, history of migraines, significant visual or hearing
impairment. Participants meeting the inclusion criteria were invited to a
separate day of testing. On the day, following randomisation, a placebo or
nicotine (7 mg) patch was applied to the participants' forearm. Three hours
later, a capsule of either amisulpride (400 mg), risperidone (2 mg) or
placebo was administered. Approximately 1.5 h later, the participants were
tested using a battery of neuropsychological and eye-movement tasks. It
consisted of (i) two WM tests (a verbal one and a non-verbal one) based on
robust evidence for WM impairment in the schizophrenia spectrum;33,41–44
(ii) a verbal fluency (VF) task based on the observation that frontal cortex
abnormalities are preferentially affected in the schizophrenia
spectrum;27,28,36,37,72 (iii) an anti-saccade eye-movement task on the basis
of it tapping inhibitory mechanisms and evidence for abnormality in the
schizophrenia spectrum;39,72,73 (iv) a smooth-pursuit eye-movement
(SPEM) task on the basis of consistent evidence for smooth-pursuit
abnormalities in schizophrenia and schizotypy.45–47 The current study
included only participants that were treated with both a placebo patch and
a placebo capsule (27 HS and 31 AS). Full details of the study from which
these subgroups were selected are detailed in previous publications.62,63
A group of LS was recruited in Manchester only using the online
database from the three-centre study described above. Participants
attended a single appointment where they provided consent, completed
the SPQ and were included if their score was ⩽ 9 and if they met the same
inclusion and exclusion criteria as described above. Included participants
completed the same testing battery as the AS and HS groups, but received
no treatment. About 35 participants were recruited of which 5 were
excluded (4 due to SPQ49 and 1 participant for having a relevant medical
history). Participant demographics are presented in Table 1.
Task descriptions
WM (N-Back) task. Series of letters (measuring 4x4 visual degrees) were
presented centrally on a monitor. Each letter remained on the screen for 1 s
and a blank screen of the same duration separated the stimuli. Participants
were instructed to respond by pressing a key when they saw a letter
identical to a preceding one with a varying number of letters between the
two target letters. The two targets followed each other in the 1-Back
condition; they were separated by one and two letters in the 2-Back and 3-
Back conditions respectively. There were also blocks to control attention to
the task where participants needed to respond when they saw a target letter
(0-Back). Before starting the task, participants completed a practice run (one
block of each condition). During the task, 3 blocks of each condition were
completed (0-Back, 1-Back, 2-Back and 3-Back) with the 12 blocks presented
pseudo-randomly. In each block 14 stimuli were presented pseudo-
randomly, so that there were 3 target and 11 non-target images. Overall,
for every WM load there was a maximum of 9 correct answers and 33
opportunities for errors of commission (that is, opportunities to respond to
an incorrect stimulus). For the purposes of statistical analysis, we extracted (i)
percentage of correct responses and (ii) number of errors of commission for
the 1-Back, 2-Back and 3-Back conditions, yielding a total of six variables.
Spatial WM task. A number of treasure chests were presented on a
monitor against a background and responses were recorded using a
computer mouse. The number of coins and chests were equal in each trial
with only one chest containing a coin at any one time. Participants
searched for all available coins by clicking on the chests and were
instructed not to choose targets they had already found coins. A practice
run with three chests was completed, followed by three blocks of four, six
and eight treasure chests, respectively (four task repetitions within each
block). Between each repetition, the configuration of the boxes on the
page was altered so that the likelihood of stereotypical searching
strategies was reduced. The outcome variables for each difficulty level
(four, six and eight chests) were: (i) average number of within trial errors
(selecting a chest previously searched within that trial) and (ii) average
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number of between trial errors (selecting a chest previously searched
within that task repetition) or a total of six variables.
VF task. Letter and category VF were assessed during a succession of 1-min
periods. In the letter VF task test, participants were asked to name as many
words as they could beginning with the letters F, A and S (FAS condition).
Names, places or numbers, as well as repetitions were categorised as errors.
In the category swap VF test, participants were asked to come up with words
from two categories (fruit and furniture) while alternating between them.
Only words consistent with the respective categories were recorded as
correct. The outcome variables for this task were (i) mean number of correct
words across the FAS condition, (ii) number of correct transitions in the
category swap condition. Total number of VF variables was 2.
Oculomotor tasks
Recording: Eye movements were recorded at 1000 Hz sampling rate
(EyeLink 1000, SR Research, Kanata, ON, Canada). Participants were seated
57 cm away from a 17-inch monitor with their head resting on a chinrest.
The target was a 0.3° diameter black dot presented on a light grey
background.
Anti-saccade task: A nine-point calibration and a practice trial were
carried out before the beginning of the task. A trial started with the black
dot in the central position of the screen (0°) for a random duration of
1000–2000 ms. The target then jumped to one of four possible peripheral
positions (±7.25°, ± 14.5°) for 1000 ms. Each of the possible locations was
used 15 times in a random order resulting in 60 trials in total. Participants
were required to look at the target in the centre and then to direct their
gaze at the exact mirror image position as fast and accurately as possible
when the target jumped to either side.
SPEM task: In the SPEM task, the target moved horizontally across the
screen (from −14.5° to +14.5°) in a sinusoidal waveform at three different
target velocities (0.25, 0.5 and 0.75 Hz). It started its movement from −14.5°.
For each of the target velocities, the target completed 10 full cycles.
Participants were asked to keep their eyes on the target as closely as possible.
Analysis: Anti-saccade data were analysed using EyeLink DataViewer
software (SR Research). Saccades were defined as having minimum
amplitude of 1° and minimum latency of 100 ms. Three variables were
extracted from the data: (i) saccade latency; (ii) directional error rate
describing the percentage of error trials (that is, trials where the
participant’s first saccade was towards the target) divided by the total
number of valid trials (that is, error trials plus correct trials, excluding eye
blink trials); (iii) saccade amplitude.
Two dependent variables were derived for the SPEM analysis using
LabView (National Instruments, Austin, TX, USA) for each of the three
speeds (six variables in total). Mean eye velocity was divided by target
velocity to yield time-weighted average velocity gains. The analysis
included sections in the central 50% of the ramp excluding saccades and
eye blink. Saccadic frequency (N per second) for each velocity was also
measured across the entire pursuit task at each velocity.
Intelligence quotient
IQ was determined using the National Adult Reading Test,74 a reading-
based estimate of premorbid intelligence. Participants were asked to
pronounce irregularly spelt words from a standardised written list.
Individual IQ scores were calculated on the basis of the number of
correctly pronounced words.
Statistical analysis demographic variables
The three groups were compared in terms of their demographic variables
(age; premorbid IQ (NART); years of education) and SPQ scores using one-
way analyses of variance.
Statistical analysis test battery
Research aiming to identify biomarkers of disorder by examining cognitive
performance on a battery of tests yields a number of dependent variables,
often as a function of the number of experimental conditions/stimuli
manipulations.
In such exploratory studies, this yields a large number (6 × 30= 180) of
potential associations that very often exceeds the number of participants.
Traditionally, this problem is addressed by choosing a candidate
univariate-dependent variable and relevant predictors and a model is
constructed using multiple-variable regression. This process is repeated for
all dependent variables of interest, leading to the potential problem of
accounting for Type II ‘false discovery’ errors at the hypothesis testing
stage.75,76
An alternative approach is to use data-driven multivariate methods such
as principal component analysis to expose the latent structure in a single
set of multivariate data, by finding a set of basis vectors onto which
observations are projected. This yields a lower dimensional—more
parsimonious—representation that explains the largest amount of
variance in the data. While this may reduce the number of regression
models required, it is agnostic to relationships between the predictors and
measurements and there is no a priori guarantee that the reduced set of
variables will be significantly smaller than the original.
To address these potential issues, we used a two-stage approach. There
were two sets of multivariate data, X and Y, representing sets of all
observations of the P= 6 predictors (schizotypy group, study site, sex, years
of education, predicted IQ score and age) and q = 23 candidate biomarkers,
respectively. Rather than search for separate reduced-dimensional repre-
sentations of X and Y independently (that is, using principal component
analysis), we first used canonical correlation analysis (CCA)77 combined
with relevance network detection to extract relationships of interest.78 CCA
is a technique whereby two sets of multivariate data (in this context,
representing multiple demographic and clinical predictors and multiple
cognitive battery testing outcomes) can be simultaneously reduced in
dimension, exposing any latent structure while maintaining the maximum
correlation between the reduced-dimensionality representations. The
standard linear regression model is a special case of this method.77 The
Table 1. Summary of the GLMs
Variable Schizotypy group contrast Estimate/coefficient s.e. P-value
Years of education High vs average 0.808 0.572 0.162
Low vs average 1.915 0.557 0.001
Low vs high 1.107 0.577 0.058
Smooth pursuit velocity gain (0.25 Hz) High vs average − 0.021 0.032 0.78
Low vs average −0.096 0.031 0.005
Low vs high − 0.075 0.032 0.053
Smooth pursuit velocity gain (0.50 Hz) High vs average − 0.063 0.072 0.654
Low vs average −0.213 0.070 0.006
Low vs high − 0.150 0.073 0.099
Anti-saccade mean percentage errors High vs average 13.676 6.266 0.074
Low vs average − 7.169 6.080 0.466
Low vs high −20.844 6.366 0.003
3-Back mean number of commission errors High vs average 0.647 0.291 0.068
Low vs average −0.155 0.283 0.848
Low vs high −0.801 0.296 0.019
Abbreviation: GLM, generalised linear model. GLMs were constructed for each relevant variable from the canonical correlation analysis, with the three-level
ordinal variable schizotypy group predicting the measured task performance variable. Contrast estimates for relative levels of schizotypy (rather than beta
coefficients) and s.e. are shown. Significant results are shown highlighted in bold for confidence level Po0.05.
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advantage of CCA is that dimensionality reduction of both X and Y is
performed simultaneously while preserving maximal correlations between
observations of X and Y projected onto these reduced representations. The
CCA algorithm is applied iteratively, so that the first application—the
leading canonical variates—represents linear combinations of observations
in Y best predicted by linear combinations of observations in X.
Subsequent applications (revealing the trailing canonical variates) are less
predictive and can be discarded because they explain less of the data;
analogous to extracting principle components by only keeping the largest
eigenvectors.79
The computed canonical variates of X and Y are labelled UL and VL,
respectively, with L= [1, 2, 3, …, min(p, q)]. We chose the first two or three
of these canonical variates and then computed another set of equiangular
vectors between UL and VL such that ZL=UL+VL. Each observation in X and
Y was then projected onto ZL (by inner products), which is equivalent to a
correlation measure between each observation in X and Y with the vectors
Z. Then a similarity score—representing association—was computed by
summing over these projections.78 These scores were then visualised
showing a network of variates in X and Y with the similarity scores
representing association strength. By adjusting a threshold T= [0,1] over
these scores, the visualised network is made simpler or more complex by
only showing higher association (as T approaches unity) or by allowing
more liberal thresholds (as T approaches zero), respectively. Those
variables which appear in the relevance network are then candidates for
further analysis in this instance using regression analyses. To illustrate the
effect of the ordinal variables on the biomarker variables, contrasts were
computed using Tukey’s Honest Significant Difference (HSD) test for
multiple comparisons.
Ethical approval
The study was approved by The University of Manchester Ethics committee
(reference number 08176) and carried out in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki.
RESULTS
Demographics
The three groups did not differ significantly in terms of age (F
(2,85) = 1.454, P= 0.24), IQ (F(2,85) = 0.043, P= 0.96) and gender (LS
group 13 f and 14 m; AS group 16 f and 15 m; HS group 15f and
15 m; χ2(2) = 0.026, P= 0.98). The years of education model was
statistically significant (F(2,85) = 5.949, P= 0.004), which was due to
the LS group having significantly more years of education relative
to the AS group but not the HS group (Table 1).
Cognitive tests analysis
We conducted the exploratory CCA on all six demographic
variables. Of the measured biomarker variables, we removed those
which were of no interest, that is, cognitive performance at the
control (‘0-Back’) condition of the N-Back task. To avoid difficulties
with matrix calculations and data imputation involved in CCA, we
only included participants with complete data sets on all
demographic and biomarker variables, leading to the inclusion
of n= 83 participants to derive the relevance network (five LS
participants excluded). The final sample size was LS 22, AS 31
and HS 30.
Using the first L= [1,2,3] canonical variates and a liberal threshold
T=0.35, we were able to derive a relevance network, which
revealed associations that might be usefully subjected to regression
analyses to quantify association of a given demographic variable (in
X) with its associated biomarker (in Y) shown in Figure 1a.
Of all the demographic variables (schizotypy group, study site,
sex, years of education, predicted IQ score and age), in X,
schizotypy group was the only variable showing associations in
the relevance network. Years of education had relatively weak
Figure 1. (a) Relevance network extracted from complete data set (dotted lines—negative correlation between variables; solid lines—positive
correlation between variables; numbers indicate direction and strength of association); corresponding generalised linear models (GLMs) for
ordinal schizotypy group predicting mean number of commission errors on 3-Back task; (b) mean percentage errors for anti-saccade task; (c)
mean pursuit velocity gain (° per second) at target velocities of 0.25 and 0.5 Hz; (d) significant multiple general linear hypothesis tests (Tukey
contrasts) for low, average and high schizotypy are show with P-values for each GLM.
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associations, which did not survive the T threshold. For the
candidate biomarkers, Y, the schizotypy group relevance network
showed negative associations for velocity gain on the (i) 0.25 Hz
and (ii) 0.50 Hz sinusoid smooth-pursuit task and positive
associations between (iii) mean percentage errors on the
oculomotor anti-saccade task and (iv) mean number of commis-
sion errors on the 3-Back WM task. The relevance network did not
demonstrate significant associations between schizotypy and the
Spatial WM or VF variables.
To explore the quantitative relationship between the relevant
variables, generalised linear models were constructed for schizo-
typy group (as an ordinal variable) and the 3-Back commission
errors (Figure 1b), the mean percentage errors on the anti-saccade
task (Figure 1c) and the ratio of velocity gain scores for the two
SPEM variables (Figure 1d). To illustrate the effect of schizotypy
group (low, average and high) on the biomarker variables,
contrasts were computed using Tukey’s HSD for multiple
comparisons (Table 2). The results confirmed the observed main
effect of schizotypy group and demonstrated that LS vs HS
comparisons were more consistently statistically significant
relative to AS vs HS comparisons. With respect to the anti-
saccade error rate and N-Back errors of commission, the LS vs HS
comparison was statistically significant while the AS vs HS
comparison approached significance. In the SPEM models, the
LS group performed significantly better than the AS group and the
LS vs HS comparisons were significant at trend level. In contrast
there was no significant difference between AS and HS groups in
terms of SPEM performance.
DISCUSSION
The objective of this study was to clarify the relationship between
levels of schizotypy and neurocognition by comparing the
cognitive performance of three groups of healthy volunteers
defined by their SPQ scores. Participants were assessed on a range
of neuropsychological and eye-movement tests that are abnormal
across the schizophrenia spectrum to establish whether LS or AS is
the optimal control group for comparison with HS in translational
studies of cognitive enhancers.
Of the candidate biomarker variables in the five tasks, those that
measured inhibitory control and had sufficient difficulty, were
most sensitive to schizotypy. For example, in N-Back, only errors of
commission (dependent on the ability to inhibit responses to
irrelevant stimuli) at the most difficult condition (3-Back) showed
HS performing worse than LS. In contrast, the groups did not differ
in percentage of correctly identified N-Back stimuli or any spatial
WM variables. Similarly, in the anti-saccade task (where inhibitory
control is crucial) HS made significantly more errors relative to LS
and AS. In the SPEM task, only the 0.25 and 0.50 Hz conditions
were sensitive to schizotypy levels, but importantly this effect was
evident only in comparisons between LS and HS. In the 0.75 Hz
condition, the groups did not significantly differ suggesting that
all participants found this condition difficult. The follow-up
regression models confirmed that for each of the four variables,
where the CCA model identified a schizotypy effect, the LS vs HS
comparisons showed more robust and significant effects relative
to AS vs HS (Table 2).
These data indicate that differences in performance on
cognitive and oculomotor tasks are largest between LS and HS
groups. This is consistent with the ‘fully dimensional’ model of
schizotypy,65 which has recently been supported by convergent
lines of evidence.80 For example, the latent structure of schizotypy
personality features were found to fit a dimensional distribution in
a taxomeric analysis.69 In addition, psychotic-like experiences
(hallucinations and delusional ideation) in the general population
fit a continuous distribution.67,68 These findings are of particular
relevance to translational studies seeking evidence for cognitive
enhancer efficacy, that is, enrichment of schizotypy studies is best
achieved by comparing LS and HS groups while using tasks that
maximise the extent of cognitive difference between these
groups. The potential utility of such enrichment is highlighted
by our finding that on a number of measures HS were
indistinguishable from the control groups. This argues that
psychometrically defined schizotypes are a high functioning
population, a conclusion consistent with the practice of schizotypy
studies recruiting participants among university and college
students. Also while some studies do not find difference in
cognition between HS and controls (either LS or AS) abnormal
functional imaging response is demonstrable.21 This demonstrates
the risks involved in using a single task to assess cognition in this
Table 2. Demographics and descriptives
Variable Low
schizotypy
Average
schizotypy
High
schizotypy
Mean s.d. Mean s.d. Mean s.d.
Demographics
SPQ score 3.8 3.1 27.8 4 50.1 6.1
Age 25.3 5.0 23.8 4.6 25.4 5.8
Premorbid IQ (NART) 114.2 6.2 114.2 4.9 113.8 6.0
Years of education 16.3 2.2 15.5 1.7 17.4 2.6
N-Back percentage correct
1-Back 99.6 0.8 99.5 0.7 97.8 0.8
2-Back 92.2 2.6 96.2 2.5 94.7 2.8
3-Back 86.7 2.3 83.3 2.3 78.1 2.5
N-Back errors of commission
1-Back 0.1 0.1 0.1 0.1 0.3 0.1
2-Back 0.1 0.1 0.0 0.1 0.2 0.1
3-Back 0.1 0.2 0.7 0.2 1.4 0.2
Spatial working memory between search errors
Load 1 0.1 0.1 0.1 0.1 0.0 0.1
Load 2 0.7 0.2 0.5 0.2 0.5 0.2
Load 3 1.0 0.4 2.0 0.4 2.0 0.4
Spatial working memory: within search errors
Load 1 0.0 0.0 0.1 0.0 0.0 0.0
Load 2 0.2 0.1 0.1 0.1 0.3 0.1
Load 3 0.6 0.3 0.5 0.3 0.4 0.3
Verbal fluency: mean number correct words
FAS task 14.6 4.0 15.5 4.3 13.7 3.6
Category swap task 7.7 1.4 8.0 1.5 7.1 1.3
Verbal fluency: mean number correct transitions
Category swap task 6.8 0.3 7.7 0.3 7.4 0.3
Anti-saccade
Errors 28.2 17.1 36.2 24.2 49.5 26.3
Amplitude gain 119.4 23.5 122.2 28.0 116.1 37.1
Peak velocity 295.8 47.3 302.3 70.9 298.4 63.4
Smooth pursuit eye-movement task: velocity gain
0.25 Hz velocity 97.1 4.7 89.9 10.2 91.24 8.7
0.50 Hz velocity 84.2 14.4 78.9 15.9 82.3 14.4
0.75 Hz velocity 67.4 20.7 61.1 23.2 67.3 20.1
Smooth pursuit eye-movement task: saccadic frequency
0.25 Hz velocity 0.8 0.4 0.9 0.4 0.8 0.3
0.50 Hz velocity 1.4 0.4 1.5 0.4 1.6 0.5
0.75 Hz velocity 2.3 0.5 2.2 0.6 2.5 0.7
Abbreviations: FAS task (a verbal fluency task - see Materials and methods);
IQ, intelligence quotient; NART, National Adult Reading Test; SPQ,
Schizotypal Personality Questionnaire.
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high functioning group. A popular approach in schizophrenia6 and
Alzheimer’s disease81 research, and adopted for this study, is to
use a battery of tests.62,63,82 However, this strategy risks increasing
the false positive rate through multiple comparisons.75,76 We
sought to address this issue by performing a canonical analysis77
which identified the variables where a significant effect of
schizotypy was present thereby greatly reducing the number of
post hoc comparisons. We propose that similar analyses should be
used in the initial work-up of battery data sets.
The finding of preferential impairment in measures of inhibitory
processes is consistent with evidence in schizotypy,22 while
inhibitory control deficits have been proposed as core features
of schizophrenia.35 Several tests have been developed to probe
inhibition directly (for example, NP and lateral inhibition tasks). In
NP, participants are instructed to attend to previously inhibited
distractors. Normal inhibitory function leads to increased reaction
times to the previously ignored stimulus. In both patients with
schizophrenia and schizotypes, this delay is diminished.36,37,83
Lateral inhibition is based on the observation that conditioning to
a stimulus is slower if it has previously been presented without
consequence. Similar to NP, the period of conditioning is
shortened in schizophrenia patients84 and schizotypes.72,85,86
Successful inhibition is critical for complex cognitive functions
such as WM, which has emerged as a potential endophenotype
of schizophrenia.87 This is based on studies reporting subtle
WM impairment in individuals with genetic88,89 and
phenomenological90,91 vulnerability to schizophrenia. The cur-
rently reported N-Back performance in schizotypes adds to a
growing body of evidence showing WM impairment in
schizotypy.33,41,44 Our data also highlight that not all WM tasks
are sensitive to schizotypy. Instead it appears that elements
directly relevant to inhibition are more useful in this high
functioning group.
Failure of the HS group to inhibit saccades in the anti-saccade
task also replicates previous findings.39,40,46,73,92 This abnormality
is again shared between HS and schizophrenia patients47 and was
recently shown to be dependent on a neural circuitry encom-
passing putamen, thalamus, cerebellum and visual cortex.72 We
also found that saccade gain during SPEM was lower in HS, a
finding replicating previous studies.45,46 The ability to follow a
visual object moving at constant speed depends on a fronto-
parieto-occipital network, which projects an expected target
trajectory to the motor cortex.93 The generated prediction is then
continuously corrected with occipital cortex tracking data.
Evidence regarding the neural basis of smooth-pursuit impairment
in schizotypy comes from a fMRI study demonstrating lower BOLD
occipital signal.94 This finding is compatible with reports of
abnormal occipitally generated evoked responses in schizotypy32
and schizophrenia.95–97 It is known that sensory cortex is under
frontal cortex modulatory control98 and it may be that a primary
dysfunction in these afferents underlies the observed occipital
deficit.99
Limitations
There are several limitations of this exploratory analysis. Firstly, the
AS and HS groups were recruited as part of a larger placebo-
controlled study which investigated the effects of acute admin-
istration of risperidone, amisulpride and nicotine on cognition. AS
and HS participants were required to attend two appointments
(treatment was given, and data on treatment effects on cognitive
performance were obtained, on the second, full-day appoint-
ment), were placebo-treated and were recruited from three sites
in the UK. In contrast, the LS group attended a single 3-h
appointment in which the data were recorded, did not receive
placebo medication and were recruited in Manchester only. We
therefore cannot rule out the possibility that the superior
performance of the LS group was due to these protocol
differences. It is feasible that fatigue or placebo effects could
have led to reduced performance in AS relative to LS groups.
However, the superior performance of the LS group was confined
solely to measures where a difference between the placebo-
treated AS and HS groups was already evident and for which
compelling evidence for an abnormality in the schizophrenia
spectrum already exists. The lack of schizotypy effect on other
tasks argues against a generalised placebo or fatigue effects-
driven cognitive superiority in the LS group. Secondly, AS group
had a significantly lower number of years of education compared
with the LS group. We accounted for this significant difference by
including years of education as a predictor in the canonical testing
and the results showed that this variable did not have a significant
independent effect on the biomarker variables. In addition, the
groups did not differ in terms of projected IQ, a measure arguably
more relevant to cognition research than years of education which
tends to reflect socio-economic status. Finally, we did not have
information on the family history of schizophrenia among the
participants—it is possible that the groups were different in this
respect.
CONCLUSION
In summary, this study explored the neurocognitive correlates of
low, average and high schizotypy. The results revealed an
impairment that primarily affected inhibitory processes in HS
subjects. Importantly we found that the performance of AS
subjects in these tests was intermediate between that of LS and
HS subjects. These results argue in favour of the fully dimensional
theory of schizotypy and strongly suggest that subjects with LS
are the most appropriate control group for further experimental
medicine schizotypy studies with putative cognition enhancing
agents for the treatment of cognitive deficits in schizophrenia.
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